Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Ancient Arthritis: RheumMadness 2022 Dinosaur SpA Scouting Report

Virginia Commonwealth University Rheumatology Fellowship Program: David Shoemaker, MD; Evan Dombrosky, MD; Nima Madanchi, MD; Abhishek Nandan, MD; & Huzaefah Syed, MD  |  February 14, 2022

Spondyloarthropathy is an ancient form of arthritis shared by multiple orders and classes of the animal kingdom. Camarasaurus, a genus of quadrupedal, herbivorous dinosaur, holds the record for the earliest known case of spondyloarthropathy—147 million years ago.

Standing on a Hidden Burden: The Oft-Overlooked Problem of Foot and Ankle Osteoarthritis

Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report

Wake Forest School of Medicine Rheumatology Fellowship Program: Khiem Vu, MD; Alyssa Strazanac, MD; John Herion, DO; & Rami Diab, MD  |  February 14, 2022

Daily living, such as walking, jumping and going up stairs, can be difficult for patients with osteoarthritis (OA). Research on the regenerative limbs of the axolotl and the human ankle provides insights into the potential of this process in humans and its implications for hip, knee and ankle OA.

An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

Residents from the RheumMadness Leadership Team: Michael Macklin, MD, PharmD; Ben Kellogg, MD; Lauren He, MD; & David Leverenz, MD  |  February 8, 2022

According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.

Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report

Mass General Hospital Rheumatology Fellowship Program: Guy Katz, MD; Ian Cooley, MD; Duncan Moore, MD; Jacquelyn Nestor, MD, PhD; & Steven Witte, MD, PhD  |  February 8, 2022

CD19 chimeric antigen receptor T (CAR-T) cell therapies may have the potential to treat rheumatic diseases in which current therapeutic options are limited, such as lupus, interstitial lung disease and systemic sclerosis.

Order in the Inflammatory Mess: RheumMadness 2022 Cytokine Networks Scouting Report

Rheumatology Leadership Team: David Leverenz, MD; Akrithi Udupa, MD; Guy Katz, MD; Lauren He, MD; Ben Kellog, MD; Michael Macklin, MD; Courtney Bair; Matthew Sparks, MD; & Lisa Criscione-Schreiber, MD, MEd  |  February 8, 2022

Research has identified and described a pro-inflammatory cytokine network shared by four rheumatic conditions that may be particularly active in patients with severe disease.

‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report

The UNC Rheumatology Fellowship Program: Leah Bettner, MD; Shruti Chandramouli, MD; Christopher Overton, MD; Astia Allenzara, MD; Michael Cunningham, MD; & Luis Palomino, MD  |  February 8, 2022

Neutrophil extracellular traps (NETs) contribute to the pathogenesis of multiple autoimmune diseases. And research has shown that patients with antiphospholipid syndrome (APS) have higher levels of circulating anti-NET antibodies than healthy controls, indicating a potential biomarker.

Risankizumab Effective Against Refractory Psoriatic Arthritis

Matthew Phelan  |  January 22, 2022

NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…

Lab Study Suggests Zinc May Worsen Rheumatoid Arthritis

Marilynn Larkin  |  January 22, 2022

NEW YORK (Reuters Health)—Zinc supplementation may exacerbate rheumatoid arthritis (RA), new laboratory data suggest. In monocytes from patients with RA, researchers found high concentrations of intracellular zinc, which regulates immune responses by affecting signaling pathways, according to a report in Science Signaling.1 They also found increased expression of Zip8, a zinc-specific importer, in peripheral and…

At Least 1 Year on Bisphosphonates Needed for Fracture Prevention

Lisa Rapaport  |  December 14, 2021

(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…

FDA Authorizes New Long-Acting, Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

U.S. Food & Drug Administration   |  December 13, 2021

On Dec. 8, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences